immunotherapyfirst-line chemotherapychemotherapychemo/IOdurvalumabatezolizumab
…en 2020-2023 and received chemo/IO. Among patients treated with immunotherapy, 563 (87.4%) received atezolizumab; 61 (9.5%) received durvalum…
1articles mentioning treatments
4treatment mentions
1distinct treatments extracted
0%of mentions human-reviewed
Active filtersEntity: chemo/IO ×
chemo/IO
This treatment is selected. Its supporting articles are shown below.